Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
1997 2
1999 2
2000 4
2002 1
2004 1
2005 1
2006 1
2007 2
2008 1
2009 3
2010 3
2011 1
2012 5
2013 6
2014 4
2015 6
2016 4
2017 1
2018 1
2020 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Validation of a self-reported HIV symptoms list: the ISS-HIV symptoms scale.
Bucciardini R, Pugliese K, Francisci D, Costantini A, Schiaroli E, Cognigni M, Tontini C, Lucattini S, Fucili L, Di Gregorio M, Mirra M, Fragola V, Pompili S, Murri R, Vella S. Bucciardini R, et al. Among authors: fragola v. AIDS Res Ther. 2016 Apr 9;13:18. doi: 10.1186/s12981-016-0102-2. eCollection 2016. AIDS Res Ther. 2016. PMID: 27064450 Free PMC article.
HIV-1 coreceptor switch during 2 years of structured treatment interruptions.
Baroncelli S, Galluzzo CM, Andreotti M, Pirillo MF, Fragola V, Weimer LE, Giuliano M, Vella S, Palmisano L. Baroncelli S, et al. Among authors: fragola v. Eur J Clin Microbiol Infect Dis. 2013 Dec;32(12):1565-70. doi: 10.1007/s10096-013-1911-z. Epub 2013 Jul 4. Eur J Clin Microbiol Infect Dis. 2013. PMID: 24213914 Clinical Trial.
Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens.
Baroncelli S, Pirillo MF, Galluzzo CM, Antoni AD, Ladisa N, Francisci D, d'Ettorre G, Segala D, Vivarelli A, Sozio F, Cirioni O, Weimer LE, Fragola V, Parruti G, Floridia M. Baroncelli S, et al. Among authors: fragola v. AIDS Res Hum Retroviruses. 2015 Jan;31(1):71-7. doi: 10.1089/AID.2014.0060. AIDS Res Hum Retroviruses. 2015. PMID: 25092266 Free PMC article.
Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir.
George EC, Bucciardini R, Richert L, Dedes N, Fragola V, Nieuwkerk P, Spire B, Volny-Anne A, West B, Molina JM, Horban A, Fox J, Pozniak A, Vella S, Termote M, Raffi F; NEAT 001/ANRS 143 Study Group. George EC, et al. Among authors: fragola v. J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):519-526. doi: 10.1097/QAI.0000000000001844. J Acquir Immune Defic Syndr. 2018. PMID: 30234665 Free PMC article. Clinical Trial.
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group. Lambert-Niclot S, et al. J Antimicrob Chemother. 2016 Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24. J Antimicrob Chemother. 2016. PMID: 26702926 Free article. Clinical Trial.
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.
Dickinson L, Gurjar R, Stöhr W, Bonora S, Owen A, D'Avolio A, Cursley A, Molina JM, Fäetkenheuer G, Vandekerckhove L, Di Perri G, Pozniak A, Richert L, Raffi F, Boffito M; NEAT001/ANRS143 Study Group. Dickinson L, et al. J Antimicrob Chemother. 2020 Mar 1;75(3):628-639. doi: 10.1093/jac/dkz479. J Antimicrob Chemother. 2020. PMID: 31754703 Clinical Trial.
A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection.
Floridia M, Tomino C, Bucciardini R, Ricciardulli D, Fragola V, Pirillo MF, Amici R, Giannini G, Galluzzo CM, Andreotti M, Seeber AC, Ammassari A, Cingolani A, Lazzarin A, Scalise G, Cargnel A, Suter F, Milazzo F, Pastore G, Moroni M, Ciammarughi R, Pini R, Carosi G, D'Amato C, Contu L, Concia E, Bonazzi L, Aiuti F, Vigevani G, Vella S; ISS-IP1 Clinical Investigators. Floridia M, et al. Among authors: fragola v. AIDS Res Hum Retroviruses. 2000 Nov 20;16(17):1809-20. doi: 10.1089/08892220050195775. AIDS Res Hum Retroviruses. 2000. PMID: 11118067 Clinical Trial.
Recent advances in antiretroviral therapy of HIV infection.
Vella S, Fragola V, Palmisano L. Vella S, et al. Among authors: fragola v. J Biol Regul Homeost Agents. 1997 Jan-Jun;11(1-2):60-3. J Biol Regul Homeost Agents. 1997. PMID: 9418165 Review. No abstract available.
Retention in Care of Adult HIV Patients Initiating Antiretroviral Therapy in Tigray, Ethiopia: A Prospective Observational Cohort Study.
Bucciardini R, Fragola V, Abegaz T, Lucattini S, Halifom A, Tadesse E, Berhe M, Pugliese K, Binelli A, De Castro P, Terlizzi R, Fucili L, Di Gregorio M, Mirra M, Olivieri E, Teklu T, Zegeye T, Haile A, Vella S, Abraham L, Godefay H; CASA-project Health Facilities. Bucciardini R, et al. Among authors: fragola v. PLoS One. 2015 Sep 4;10(9):e0136117. doi: 10.1371/journal.pone.0136117. eCollection 2015. PLoS One. 2015. PMID: 26340271 Free PMC article.
47 results